| 產(chǎn)品名稱(chēng) | HCC70 |
|---|---|
| 商品貨號(hào) | B164576 |
| Organism | Homo sapiens, human |
| Tissue | mammary gland; breast/duct |
| Cell Type | Epithelial |
| Product Format | frozen |
| Morphology | epithelial |
| Culture Properties | adherent, The line grows as attached medium-sized epithelial cells without floating cells. |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | TNM stage IIIA, grade 3,primary ductal carcinoma |
| Age | 49 years |
| Gender | female |
| Ethnicity | Black |
| Applications | HCC70 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19. However, recent studies performed outside of ATCC have given conflicting results about the status of the estrogen receptor for these cells. The cells are poorly differentiated. The cells overexpress p53, and are negative for the expression of Her2-neu oncogenes. The depositor of CRL-2315 initially reported the cells were positive for estrogen receptors. |
| Storage Conditions | liquid nitrogen vapor phase |
| Karyotype | polyploid |
| Images |  |
| Derivation | The HCC70 cell line was initiated from a primary ductal carcinoma on June 3, 1992, and took 44 months to establish. |
| Clinical Data | 49 years Black female |
| Receptor Expression | progesterone receptor, not expressed |
| Oncogene | her2/neu -, p53 + (overexpressed) |
| Genes Expressed | Epithelial glycoprotein 2 [EGP2]; cytokeratin 19,her2/neu -, p53 + (overexpressed),The cells overexpress p53, and are negative for the expression of Her2-neu oncogenes.,The depositor of CRL-2315 initially reported the cells were positive for estrogen receptors. |
| Cellular Products | Epithelial glycoprotein 2 [EGP2]; cytokeratin 19 |
| Comments | The HCC70 cell line was initiated from a primary ductal carcinoma on June 3, 1992, and took 44 months to establish. The cells are poorly differentiated. The tumor was classified as TNM Stage IIIA, grade 3, invasive ductal carcinoma with metastases in 4 out of 17 lymph nodes. The cells overexpress p53, and are negative for the expression of Her2-neu oncogenes. HCC70 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19. The depositor of CRL-2315 initially reported the cells were positive for estrogen receptors. However, recent studies performed outside of ATCC have given conflicting results about the status of the estrogen receptor for these cells. An independent study, by ATCC Scientists, is underway to assess the estrogen receptor status; results of this study will be published online upon completion. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing | Protocol:
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days |
| Cryopreservation | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| STR Profile | Amelogenin:X CSF1PO:10,14 D13S317:12 D16S539:9,13 D5S818:12,13 D7S820:10,11 THO1:9 TPOX:10 vWA: 13,15 |
| Name of Depositor | AF Gazdar, AK Virmani |
| Deposited As | Homo sapiens |
| Year of Origin | 1992 |
| References | Kao J, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PlosONE 4 (7): e 6146, 2009 Kim MS, et al. Breast cancer diagnosis using a microfluidic multiplexed immunohistochemistry platform. PlosONE 5 (5): e10441, 2010 Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771 |
| 序號(hào) | 文章標(biāo)題 | 操作 |
|---|---|---|
| 1 | ATCC細(xì)胞運(yùn)輸和處理 | 查看詳情 |
| 2 | 其他海外品牌代理 | 查看詳情 |
| 3 | ATCC代理 | 查看詳情 |
| 4 | 購(gòu)買(mǎi)須知 | 查看詳情 |
| 5 | 訂購(gòu)流程 | 查看詳情 |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
